Jyong Biotech Touts Dual-Action Drug for Cancer and Cholesterol

NEW TAIPEI CITY, Taiwan – February 12, 2026 – Jyong Biotech Ltd. (Nasdaq: MENS) today announced a significant milestone for its lead drug candidate, MCS-8, revealing Phase II clinical trial data that suggests the plant-derived therapeutic may be a 'dual-action' agent, simultaneously reducing the risk of prostate cancer and improving metabolic health. The announcement positions the company at a pivotal crossroads, armed with promising clinical results while navigating ambitious commercial expansion plans in Asia and considerable financial pressures.

The Taiwanese biotechnology firm reported that its 700-subject study not only met its primary goal in cancer prevention but also uncovered unexpected benefits in regulating cholesterol. This dual potential could significantly broaden the drug's market appeal, targeting two of the most pervasive health issues in aging populations. However, the path forward involves costly Phase III trials and hinges on converting preliminary international partnerships into concrete revenue streams.

A 'Two-for-One' Breakthrough in Preventative Medicine?

The core of Jyong Biotech's announcement is the successful completion of its Phase II trial for MCS-8, a randomized, placebo-controlled study conducted across 20 medical centers in Taiwan. The results, from a trial registered on ClinicalTrials.gov as NCT02042807, are compelling.

Data showed a statistically significant 27.3% reduction in the overall incidence of prostate cancer for subjects taking MCS-8 compared to a placebo. Perhaps more clinically profound was the 17.1% reduction in high-grade prostate cancer (Gleason Score ≥ 7). This specific type of cancer is the primary driver of mortality, and developing effective preventative agents against it has been a long-standing challenge in oncology.

Beyond just incidence rates, the data suggests MCS-8 has a tangible biological effect on tumor burden. The trial noted a 35.2% reduction in the percentage of positive biopsy cores and a 24.4% reduction in the cancer-positive area within those cores, offering a potential alternative to the stressful 'active surveillance' model many at-risk men currently endure.

What truly elevates the potential of MCS-8, however, is its serendipitous discovery as a metabolic regulator. Over the two-year trial, patients on MCS-8 displayed a statistically significant reduction in total cholesterol (P = 0.036). The lipid-modulating effects were consistent, with trends showing decreased triglycerides (P = 0.05) and 'bad' LDL cholesterol (P = 0.018), alongside a significant increase in 'good' HDL cholesterol (P = 0.003). This is scientifically significant, as oncological research has increasingly documented a link between metabolic syndrome—characterized by poor lipid profiles and high blood sugar—and the progression of prostate cancer. The ability of MCS-8 to address both fronts suggests a powerful synergistic mechanism.

Furthermore, the drug demonstrated a strong safety profile. No serious adverse events were linked to MCS-8, and it showed no negative impact on blood pressure, liver, or kidney function. An analysis of the enzyme LDH, a marker for cellular damage, showed stable levels in the MCS-8 group, while the placebo group saw a significant increase, reinforcing the drug's potential for safe, long-term prophylactic use.

"The Phase II data for MCS-8 is particularly exciting because it addresses two of the most prevalent health concerns in the aging male population: prostate cancer risk and metabolic health," stated Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech, in the company's press release. "We have established a strong scientific foundation for our global Phase III trials in the future."

An Ambitious Asian Strategy

Parallel to its clinical advancements, Jyong Biotech is aggressively pursuing a commercialization strategy focused on key Asian markets for another of its candidates, MCS-2. The company has formalized a non-binding Letter of Intent (LOI) with a major South Korean pharmaceutical company to explore in-licensing the drug. The potential partner is described as a premier supplier to hospitals and clinics, possessing the infrastructure to navigate South Korea's sophisticated regulatory and reimbursement landscape.

Jyong has also expanded into Southeast Asia via a Memorandum of Understanding (MOU) with a specialized pharmaceutical distributor in Ho Chi Minh City, Vietnam. This agreement kicks off the due diligence process for bringing MCS-2 into a market characterized by a rapidly aging population and a pharmaceutical sector projected to reach over $12 billion by 2030. These partnerships represent a strategy to leverage local expertise for faster market access.

However, it is crucial to note that both the LOI and MOU are non-binding. While they signal strong initial interest and open the door for negotiations, they do not guarantee that definitive commercial agreements will be finalized.

Financial Headwinds and Investor Scrutiny

Despite the scientific promise, Jyong Biotech faces a challenging financial reality. As a development-stage company, it has not generated revenue in recent years and reported a net loss of $1.25 million for the last quarter of 2025. Public filings from mid-2025 revealed a precarious financial state with just $99,000 in cash against $41.4 million in total liabilities and a significant shareholders' deficit.

The company's stock (MENS) has reflected this uncertainty, experiencing extreme volatility. In late 2025, after being flagged as significantly overvalued by some analysts, the stock price plummeted, highlighting investor caution surrounding the firm's financial health and its ability to fund future operations.

Successfully launching a global Phase III trial for MCS-8—a necessary and costly step for regulatory approval in major markets like the U.S. and Europe—will require a substantial capital injection. The company's ability to secure this funding, either through partnerships or capital markets, remains the most critical hurdle to realizing the potential of its pipeline.

In a move that may be aimed at shoring up its financial strategy, Jyong recently appointed Wei (Vivi) Zhang, an executive with experience in IPOs and fundraising, as its new Chief Financial Officer. This change in leadership could signal a renewed push to stabilize the company's finances and secure the resources needed to carry its promising clinical assets across the finish line.